Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiRNA-Seq analysis of parental human leukemia K562 and clonal etoposide resistant K562 (designated K/VP.5) cell lines.

ABSTRACT: miRNA-Seq analysis of parental human leukemia K562 and clonal etoposide resistant K562 (designated K/VP.5) cell lines.

PROVIDER: PRJNA594370 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10611973_1.fastq.gz	Fastqsanger.gz
	SRR10611973_2.fastq.gz	Fastqsanger.gz
	SRR10611974_1.fastq.gz	Fastqsanger.gz
	SRR10611974_2.fastq.gz	Fastqsanger.gz
	SRR10611975_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

miRNA-Seq analysis of parental human leukemia K562 and clonal etoposide resistant K562 (designated K/VP.5) cell lines.

Project description:We report that ~300 mature miRNAs were detected in these cells. 73 miRNAs were overexpressed (fold change > 2; adjusted P-value < 0.05) and 14 were underexpressed (fold change > 2; adjusted P-value < 0.05) in K/VP.5 compared to K562 cells.

2020-01-31 | GSE141687 | GEO

The effect of over-expression of PRR5-VP in Arabidopsis seedlings

Project description:PRR5 transcription factor acts in the circadian clock system. To elucidate regulated genes by PRR5, Chimeric protein PRR5-VP, which activates direct target genes of PRR5, was over-expressed in Col-0. Microarray analsysis was performed using these plants with Affymetrix ATH1 genechip. PRR5-VP expressing plants and its parental plants (accession Col-0, described as Wild) were grown under 12 hr light / 12 hr dark conditions, and harvested at ZT6(6 hr after light on), ZT12, and ZT18

2012-09-20 | E-GEOD-36360 | biostudies-arrayexpress

CRISPR/Cas9 Genome Editing of the Human Topoisomerase IIα Intron-19 5′ Splice Site Circumvents Etoposide Resistance in Human Leukemia K562 Cells

Project description:Results indicate that CRISPR/Cas9 gene editing of a suboptimal E19/I19 5′ splice site in the TOP2α gene results in circumvention of acquired drug resistance to etoposide and other TOP2-targeted drugs in a clonal K562 cell line by enhancing removal of intron 19 thereby decreasing formation of a truncated TOP2α/90 isoform and increasing expression of full-length TOP2α/170 in these resistant cells.

2021-02-28 | GSE163013 | GEO

RNAseq data of VP

Project description:RNAseq data of VP in different NaCl condition

| PRJEB57782 | ENA

Monocyte membrane-coated nanoparticles (MoNP)-Verteporfin (VP) treatment alleviated the TNFalpha-induced inflammatory response in Endothelial cells

Project description:Atherosclerosis, characterized by the buildup of plaque in arteries, is a major cause of cardiovascular mortality worldwide, as there is no efficient strategy for targeted therapy. However, we have developed a new drug delivery platform called MoNP, which is loaded with VP, a potent inhibitor of YAP/TAZ signaling. To investigate the MoNP-VP treatment effect, EC were pretreated with MoNP or MoNP-VP then induced the inflammation by TNFalpha. After TNFalpha treatment, the cells were collected and extracted the RNA for RNA sequencing (RNA-Seq). The results showed that MoNP-VP significantly decreased the expression of YAP/TAZ-targeted genes and inflammatory markers while upregulating atheroprotective genes. Overall, these findings suggest that MoNP-VP has the potential to serve as an effective drug delivery platform for atherosclerosis.

2024-10-23 | GSE229918 | GEO

KMDR:K562 multi-drug resistance

Project description:To understand the underlying resistance mechanisms in response to imatinib (IMA) and adriamycin (ADR), the parental K562 cells were treated with low doses of IMA or ADR for two months to generate derivative cells with mild, intermediate and severe resistance to the drugs as defined by their increasing resistance index (RI). PulseDIA-based quantitative proteomics was then employed to reveal the proteome changes in these resistant cells

2021-12-21 | PXD030553 |

Gene expression profile in gastric cancer cells by Verteporfin (VP)

Project description:Verteporfin (trade name Visudyne) is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 689 nm[1] in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels. Recently, it was reported that VP has chemotherapeutic effect in cancer. To identify the gene expression profile in gastric cancer cells by VP, we performed microarray.

2017-12-26 | GSE77982 | GEO

Expression profiling of etoposide-induced senescent cells

Project description:We report here the RNA-seq data of proliferating IMR90 cells and etoposide-induced senescent cells with control or cGAS knockdown

2017-08-14 | GSE99028 | GEO

Vibrio parahaemolyticus strain:vp-HL-202005

Project description:Vibrio parahaemolyticus strain:vp-HL-202005 Genome sequencing

| PRJNA910996 | ENA

The effect of over-expression of PRR5-VP in Arabidopsis seedlings

2012-09-20 | GSE36360 | GEO